Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astal LaboratoriesBOM:512600 +2.62%48 EBITDA Margin % is 5.52% as of Mar. 2026, which is 18% below its 10-year median of 6.72. GuruFocus rates BOM:512600 with a GF Score™ of 48/100 and a GF Value™ of ₹52.99 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 959 Drug Manufacturers companies, Astal Laboratories ranks worse than 60.38% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Astal Laboratories's EBITDA for the
three
months ended in Mar. 2026 was ₹23 Mil. Astal Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹409 Mil. Therefore, Astal Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 5.52%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Astal Laboratories EBITDA Margin % Related Terms
Astal Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Astal Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512600 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Astal Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astal Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astal Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Astal Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astal Laboratories (BOM:512600) has a EBITDA Margin % of 5.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astal Laboratories and its competitors. This is 18% below median its historical median of 6.72. Over the past decade, Astal Laboratories' EBITDA Margin % has ranged from 1.17 to 20.09. According to the industry distribution chart, Astal Laboratories ranks #579 out of 959 companies in the Drug Manufacturers industry, placing it in the top 60.4%.
Is Astal Laboratories' EBITDA Margin % too high?
Astal Laboratories' current EBITDA Margin % of 5.52% is 18% below median its 10-year median of 6.72. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 20.09. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Astal Laboratories' value of 5.52% is 55.8% below this industry median. Based on the distribution chart, Astal Laboratories ranks #579 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astal Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Astal Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Astal Laboratories ranks #579 out of 959 companies for EBITDA Margin %. This places Astal Laboratories in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Astal Laboratories' value of 5.52% is 55.8% below this benchmark. Historically, Astal Laboratories' own EBITDA Margin % has ranged from 1.17 to 20.09 over the past decade. While the company's 10-year median is 6.72 vs. the industry median of 12.49, Astal Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astal Laboratories's current EBITDA Margin % of 5.52% is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astal Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astal Laboratories's current EBITDA Margin % is 5.52%, which is 18% below median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astal Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Astal Laboratories (BOM:512600) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹52.99, compared to a current price of ₹82.55 — trading 55.8% above its estimated fair value. The current EBITDA Margin % is 5.52%, which is 18% below median its 10-year median of 6.72 and 55.8% below the Drug Manufacturers industry median of 12.49. Astal Laboratories' overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Astal Laboratories (BOM:512600), the current EBITDA Margin % is 5.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astal Laboratories (BOM:512600) Overvalued in 2026?
Based on GuruFocus' analysis, Astal Laboratories stock appears to be overvalued.
The current stock price of ₹82.55 is trading 55.8% above its estimated GF Value™ of ₹52.99.
GuruFocus considers Astal Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:512600:
EBITDA Margin %: 5.52% (18% below median its 10-year median of 6.72)
GF Value™: ₹52.99 vs. price of ₹82.55 (55.8% above fair value)
Industry Position: 55.8% below the Drug Manufacturers median (#579 of 959)
No single metric tells the full story. See the BOM:512600 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astal Laboratories Ltd is an India-based company. The main objects of the company are to manufacture and sales of Pharmaceutical Intermediates and Bulk Drugs. The company has a single segment, i.e., Pharmaceuticals.
48GF Score
Get the complete analysis for BOM:512600
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512600 has been successfully added to your 
